BioSpace News Archive

Galmed Pharmaceuticals Ltd. announced interim results from the Open-Label Part of the ARMOR study showing fibrosis improvement with Aramchol using multimodality histological assessment.

Orthofix Medical Inc. announced that it plans to release financial results for the first quarter 2022 before market open on Friday, May 6, 2022.

Optum Rx, the pharmacy care services business of UnitedHealth Group, is donating 5,000 at-home COVID-19 rapid antigen self-tests to increase access to COVID-19 testing and support for underserved communities across Chicago.

April 28, 2022 11:00 UTC ULTOMIRIS ® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalized myasthenia gravis ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks WILMINGTON, Del.--( BUSINESS WIRE )-- ULTOMIRIS ® (rav

Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term Novocure reported financial results for the quarter ended March 31, 2022.

Moderna, Inc. today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food and Drug Administration.

Intellia Therapeutics, Inc. will present its first quarter 2022 financial results and operational highlights in a conference call on May 5, 2022, at 8 a.m. ET.

InspireMD, Inc. announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the market opens.

Nevakar Injectables Inc., a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced that the U.S. Food and Drug Administration has approved its ready-to-use Ephedrine Sulfate Injection in a prefilled syringe.

Vivos Therapeutics, Inc. announced that it plans to release financial results for the first quarter ended March 31, 2022 after market close on Monday, May 16, 2022.